Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis (NVS) reports positive data on SMA treatment from a phase III study. It also acquires Coalesce Product Development Limited to strengthen its respiratory and complex generics business.

Novartis (NVS) Announces Data on Zolgensma, Acquires Coalesce

Novartis AG (NYSE: NVS) announced new data from the completed Phase 3 SPR1NT study of Zolgensma (onasemnogene abeparvovec), a one-time treatment for spinal muscular atrophy (SMA).  The data demonstrated that children with three copies of the SMN2 backup gene who were.

Novartis's Data Reinforces Age-Appropriate Development With Zolgensma Gene Therapy Study

Basel, March 13, 2022 — Novartis today announced new data that reinforce the transformational benefit of Zolgensma® (onasemnogene abeparvovec), an essential one-time treatment for spinal muscular atrophy (SMA). The completed Phase 3 SPR1NT study demonstrated that children with three copies of the SMN2 back-up gene who were treated presymptomatically achieved age-appropriate motor milestones, including standing and walking.2 In addition, a descriptive post-hoc analyses of START, STR1VE-EU and STR1VE-US (n=65) indicated children with SMA Type 1 achieved or maintained important measures of bulbar function following treatment with Zolgensma, including ability to speak; swallow and meet nutritional needs; and maintain airway protection.3 These data are among a Zolgensma data set being presented during the 2022 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, which also include, in part, real-world data from the RESTORE registry and a chart review of US patients who changed therapy to Zolgensma.

Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection

AbbVie

Bristol-Myers

GlaxoSmithKline

Johnson & Johnson

Merck

Pfizer

As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market.

7 Drug Stocks to Consider After the Viatris Plunge

Voyager (VYGR) stock rises on the license option agreement with Novartis to get a target-specific access to next-generation TRACER AAV capsids for gene therapy programs.

Voyager (VYGR) Gains on Deal With Novartis for Gene Therapies

Voyager Therapeutics Inc.'s VYGR, +6.22% stock gained 16.8% in premarket trading on Tuesday after the gene therapy company said it inked a deal with Novartis [n: nvs] worth up to $1.7 billion. Novartis will pay $54 million upfront to license Voyager's novel adeno-associated virus (AAV) capsids for use with the gene therapies it's developing.

Voyager, Novartis sign deal worth up to $1.7 billion

Voyager Therapeutics

Novartis AG (NYSE: NVS) has entered a license option agreement with Voyager Therapeutics Inc (NASDAQ: VYGR) for three capsids to use in potential gene therapies for neurological diseases, with an option to access capsids for two other targets. Data suggest that AAV capsids.

Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs

Akebia Therapeutics

Do Food and Drug Administration decisions—thumbs up or thumbs down—affect the stock prices of companies seeking drug approvals? We're likely to find out this month as several key drugs are about to be ruled on.

Key FDA Decisions Soon on Akebia, Bristol-Myers and Novartis Drugs

Bank of Nova Scotia

British American Tobacco

Enterprise Products Partners

Altria

Realty Income Corp

V.F.

Russia's invasion of Ukraine has combined with rising interest rates and high market valuations to spark the 2022 correction.

The World's 10 Best Rich Retirement Blue-Chips You Can Safely Buy Today

2022 is a year of fear for Wall Street, with wild price swings that can potentially cause you to make a costly mistake.

Novartis Is One Of The Best High-Yield Dividend Aristocrats You Can Buy In 2022

Let's see if Novartis (NVS) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Consider Novartis (NVS) Stock Now?

Blackrock Inc

Cummins

Lowe's

PPG Industries

Stanley Black & Decker

The 2022 correction is frustrating many investors who have been spoiled by years of Buffett-like returns with almost no volatility.

9 No-Brainer Dividend Blue-Chips For A Rich Retirement

Molecular Partners AG

Molecular Partners AG MOLN and its partner Novartis AG NVS, have requested FDA Emergency Use Authorization (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19

With the proceeds from the sale of its Roche shares and its strong Free Cash Flow, Novartis AG repaid $23.6B of its debt in FY2021. Despite developing the world's most expensive drug, Zolgensma, NVS has not reported rewarding revenues from its Spinal Muscular Atrophy therapeutics.

Cash Rich Novartis AG Paid Off $23.6B Of Its Net Debt In FY2021

Contrarian idea after the Q4 results. Solid Q4 results.

Novartis: A Good Long-Term Pick

Novartis AG (NVS) CEO Vasant Narasimhan on Q4 2021 Results - Earnings Call Transcript

Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.

Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing

Novartis AG NVS reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year, benefiting from the sale of its stake in Roche Holding AG RHHBY. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues

Novartis is a large cap pharma company from Switzerland with a portfolio that is broadly diversified both in terms of products and in terms of geography.

Novartis - No Need To Rush Buying This Broadly Diversified Swiss Quality Business

Novartis says its Sandoz generics unit has received interest from private equity.

Novartis Earnings Rise, Says Review of Sandoz Unit Progressing

Novartis reported fourth-quarter core operating income gained 9% as higher drug sales offset in increase in marketing and development costs.

Novartis Q4 core operating income gains 9%

Ad hoc announcement pursuant to Art. 53 LR

Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021

How to spend $45 billion is a nice problem to have. That's the sum Swiss pharmaceutical giant Novartis AG ( NVS , Financial) will have at its disposal if a rumored sale of its Sandoz unit materializes.

Sale Rumors of Novartis' Sandoz Unit Are Heating Up

Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Novartis AG's unit NVS Sandoz, Bloomberg reports, citing people close to the matter.  Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Carlyle, Blackstone Mull $25B Buyout For Novartis' Sandoz Arm: Report

Blackstone Group

Private equity firms Blackstone Inc and Carlyle Group Inc are in talks about potentially teaming up on a bid for Swiss drugmaker Novartis' generics unit, Bloomberg News reported on Tuesday, citing people with knowledge of the matter.

Blackstone, Carlyle consider joint bid for Novartis generics unit - Bloomberg News

News for Novartis Stock (NVS)